1)Urokinase-type plasminogen activator receptor尿激酶型纤溶酶原激活物受体
英文短句/例句
1.The Relationship between the Expression of Yrokinase-type Plasminogen Activator Receptor,and the Infiltration and Metastasis of Gastric Cancer尿激酶型纤溶酶原激活物受体表达与胃癌浸润和转移过程的关系
2.Clinical Significance of Measurement of Plasma Urokinase Type Plasminogen Activator and its Receptor in Cancer Patients癌症患者尿激酶型纤溶酶原激活物及其受体检测的临床意义
3.Expression of urokinase-type plasminogen activator and its receptor protein in synovial tissues from osteoarthritis骨关节炎滑膜中尿激酶型纤溶酶原激活物及其受体蛋白的表达
4.Clinical Study of the Expression of Tissue Factor and Urokinase Plasminogen Activator Receptor in Breast Cancer组织因子、尿激酶型纤溶酶原激活剂受体在乳腺癌中的表达
5.Comparison of Recombinant Tissue Plasminogen Activator, Urokinase and Defibrase in Vitro Simulation of Thrombolytic Test重组织型纤溶酶原激活剂、尿激酶和降纤酶体外溶栓效果比较
6.Detection and clinical significance of plasma urokinase-type plasminogen activator and its soluble receptor in multiple myeloma patients;多发性骨髓瘤患者血浆尿激酶型纤溶酶原激活物及其可溶性受体的检测
7.Significance of Urokinase-type Plasminogen Activator and Urokinase-type Plasminogen Activator Receptor in Synovial Fluid of Patients with Temporomandibular Disorders;颞下颌关节紊乱病关节液中尿激酶型纤溶酶原激活物及其受体的检测
8.The Relationship of LN-R and uPA in Invasive Ductal Breast Cancer层粘连蛋白受体、尿激酶型纤溶酶原激活物在乳腺浸润性导管癌中的表达及其相关性
9.Study on Recombinant Nonglycosylated Urokinase-type Plasminogen Activator;重组非糖基化尿激酶型纤溶酶原激活剂的研究
10.Study on the Transcriptional Regulation of Urokinase Plasminogen Activator in Human Lung Cancer;尿激酶型纤溶酶原激活物在人肺癌细胞中表达调控的研究
11.The Experiment Research That the uPA to Suffer from the Relativity with the Arthritis Disease;尿激酶型纤溶酶原激活物（uPA）与关节炎性疾患相关性的实验研究
12.Expressions of Survivin and uPA in human cerebral gliomas脑胶质瘤组织中Survivin和尿激酶型纤溶酶原激活物蛋白的表达
13.Plasma Concentrations Changes and Significance of Plasminogen Activator, Plasminogen Activator Receptor and Plasminogen Activator Inhibitor-1 in Chronic Glomerulonephritis and the Intervenient Research on Them;慢性肾小球肾炎血浆纤溶酶原激活物及其受体和纤溶酶原激活物抑制剂的变化与干预研究
14.Cloning and Expression of Urokinase Type Plasminogen Activator cDNA尿激酶型纤溶酶原激活因子cDNA的克隆与原核表达
15.Expression and Regulation of Urokinase-type Plasminogen Activator in Supraglottic Laryngeal Cancer;尿激酶型纤溶酶原激活剂在声门上型喉癌中的表达及调节机制
16.Effects of Qinggan Huoxue Recipe and its separated recipes on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 fibrinolytic system in rats with alcoholic liver fibrosis清肝活血方及其拆方对酒精性肝纤维化大鼠尿激酶型纤溶酶原激活物途径的影响
17.A Study of the Level of Cyclooxygenase-2 and Urokinase-type Plasminogen Activator in the Left and Right Atrium of Acute Atrial Fibrillation in Canines;犬急性心房颤动时心房环氧酶-2与尿激酶型纤溶酶原激活物的变化
18.The Effect of Amiloride-an Inhibitor of Urokinase on the Pathology of Rat COPD Model;尿激酶型纤溶酶原激活物抑制剂—氨氯吡咪对大鼠COPD模型病理改变的影响
相关短句/例句
uPAR尿激酶型纤溶酶原激活物受体
1.Objective To observe the dynamic changes of urokinase-type plasminogen activator(uPA) and its receptor(uPAR) in rats after pulmonary thromboembolism(PTE) and their relationship to spontaneous thrombolysis rate.目的观察大鼠肺血栓栓塞症(PTE)后不同时间血浆尿激酶型纤溶酶原激活物(uPA)和尿激酶型纤溶酶原激活物受体(uPAR)的动态变化,并探讨两者与血栓自溶率的相关性。
2.Objective To study the effect of expression of urokinase-type plasminogen activator receptor (uPAR) and cathepsin D and nm23 on the infiltration and metastasis of gastric cancer and to investigate the relationship of their expression.目的 研究尿激酶型纤溶酶原激活物受体(urokinase-type plasminogen activator receptor,uPAR)、组织蛋白酶D(cathepsin D,CD)和nm23与胃癌组织学类型的关系、浸润和转移过程中所起的作用。
3)urokinase type plasminogen activator receptor尿激酶型纤溶酶原激活物受体
1.The purpose of this article is to study the effects of pro-urokinase on the expression and release of urokinase type plasminogen activator receptor(u-PAR) and plasminogen activator inhibitor1(PAI-1) and to study the effects of pro-urokinase on the mR.方法将重组尿激酶原0或150 IU/mL与人肺动脉内皮细胞共同孵育8 h,收集培养上清并应用ELISA方法检测其中尿激酶型纤溶酶原激活物受体(u-PAR)和纤溶酶原激活物抑制物-1(PAI-1)的含量;将重组尿激酶原(0~150 IU/mL)分别与HPAECs共同孵育(0~24 h),提取细胞总RNA并应用RT-PCR技术检测尿激酶型纤溶酶原激活物(u-PA)mRNA表达的变化。
4)Urokinase plasminogen activator receptor尿激酶型纤溶酶原激活物受体
1.In this investigation, we tried to test the dynamic changes of Urokinase plasminogen activator receptor (UPAR) and D-dimer (D-D ) in Cerebrospinal Fluid ( CSF) in IVH patients who received whether an intraventricular infusion of urokinase or not, and to answer the two questions.因而,临床脑室系统内应用UK,必须回答二个问题,其一是:脑室出血后脑室系统是否具有纤溶能力?其二是:如果有,那么应用外源性UK是否有助于增强纤溶的活性?本项研究通过研究脑室内灌注UK和不灌注UK的脑室出血患者脑室外引流脑脊液(Cerebrospinal Fluid,CSF)中的尿激酶型纤溶酶原激活物受体(Urokinase plasminogen act ivatorreceptor,UPAR)及D-二聚体(D-dimer,D-D)的动态变化,初步探讨这一问题材料与方法:34例脑室出血经侧脑室穿刺外引流治疗的患者,随机分为UK组和NO-UK组。
5)soluble urokinase receptor(suPAR)可溶性尿激酶型纤溶酶原激活物受体
1.Aim:To study the changes and clinical significance of soluble urokinase receptor(suPAR)and soluble intercellular adhesion molecule-1(sICAM-1)in cerebrospinal fluid(CSF)in patients with central nervous system infection(CNSI).目的:研究中枢神经系统感染(CNSI)患者脑脊液中可溶性尿激酶型纤溶酶原激活物受体(suPAR)、可溶性细胞间黏附分子-1(sICAM-1)的变化及意义。
6)urokinase-type plasminogen active receptor尿纤溶酶原激活物受体
延伸阅读
纤溶酶原分子式：CAS号：性质：无活性纤溶酶前身物。在生理条件下只要有小量纤溶酶生成，就会被抑制剂α2抗纤溶酶迅速钝化。纤溶酶原同纤维蛋白原和纤维蛋白结合形成血块时，渗入到血块中，在此情况下激活形成的纤溶酶不受α2抗纤溶酶抑制。组织中的各种纤溶酶原激活剂都是丝氨酸蛋白酶，水解纤溶酶原多肽链上的Arg-Val肽键，生成有活性的纤溶酶，可使纤维蛋白水解成可溶性降解产物，使血块溶解。
